Treatment of locally advanced NSCLC (LA-NSCLC) is focused on multimodal strategy, including chemotherapy and radiotherapy (in combination or as alternative treatments), followed by surgery in selected cases. Recently, durvalumab consolidation after definitive chemo-radiation has shown a meaningful overall survival benefit. However, it is important to note that elderly patients represent a high proportion of NSCLC population and frailty and comorbidities can significantly limit treatment options. Indeed, elderly patients are under-represented in clinical trials and data to drive treatment selection in this category of patients are scanty. Available data, main issues and controversies on multimodal treatment in elderly LA-NSCLC patients will be reviewed in this paper.

局部晚期 NSCLC (LA-NSCLC) 的治疗侧重于多模式策略，包括化疗和放疗（联合或作为替代治疗），然后在选定的病例中进行手术。最近，确定性放化疗后的 durvalumab 巩固已显示出有意义的总生存获益。然而，值得注意的是，老年患者在 NSCLC 人群中占很大比例，虚弱和合并症会显着限制治疗选择。事实上，老年患者在临床试验中的代表性不足，推动此类患者治疗选择的数据很少。本文将综述老年 LA-NSCLC 患者多模式治疗的现有数据、主要问题和争议。